CytomX Therapeutics (CTMX) Total Debt (2014 - 2015)

CytomX Therapeutics (CTMX) posted Total Debt of $78000.0 for Q4 2015, down 97.39% on a QoQ basis from $3.0 million in Q4 2014, and down 97.39% year-over-year from $3.0 million in Q4 2014.

CytomX Therapeutics (CTMX) Total Debt (2014 - 2015) Analysis & Trends

CytomX Therapeutics' Total Debt history runs 2 years deep, the most recent figure standing at $78000.0 for Q4 2015.

  • Quarterly Total Debt fell 97.39% year-over-year to $78000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $78000.0 (down 97.39% YoY) and the FY2015 annual result came in at $78000.0, down 97.39% from the prior year.
  • Total Debt was $78000.0 for Q4 2015 at CytomX Therapeutics, down from $3.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $3.0 million in Q4 2014 and bottomed at $78000.0 in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 110.96 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 959.06 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 CytomX Therapeutics 574.36 Mn 227.66 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2015 78,000.00
Dec 31, 2014 2.99 Mn